Nestle To Buy $2.6B Peanut Allergy Drug Developer
Nestle revealed plans Monday to buy biopharmaceutical company Aimmune Therapeutics, which developed the first federally approved peanut allergy drug for children, in an all-cash deal that values Aimmune at $2.6 billion...To view the full article, register now.
Already a subscriber? Click here to view full article